These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia. Naito Y; Hamaoka S; Kinoshita M; Kainuma A; Shimizu M; Katoh H; Moriyama K; Ishii KJ; Sawa T Microbiol Immunol; 2018 Dec; 62(12):774-785. PubMed ID: 30378708 [TBL] [Abstract][Full Text] [Related]
8. In-Silico Analysis and Protective Efficacy of the PcrV Recombinant Vaccine against Pseudomonas Aeruginosa in the Burned and PA-Infected BALB/c Mouse Model. Fakoor MH; Owlia P; Mousavi Gargari SL; Sabokbar A Iran J Immunol; 2020 Jun; 17(2):121-136. PubMed ID: 32602466 [TBL] [Abstract][Full Text] [Related]
9. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice. Moriyama K; Wiener-Kronish JP; Sawa T Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258 [TBL] [Abstract][Full Text] [Related]
10. The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa. Kinoshita M; Kato H; Yasumoto H; Shimizu M; Hamaoka S; Naito Y; Akiyama K; Moriyama K; Sawa T Hum Vaccin Immunother; 2016 Nov; 12(11):2833-2846. PubMed ID: 27454613 [TBL] [Abstract][Full Text] [Related]
11. Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge. Neely AN; Holder IA; Wiener-Kronish JP; Sawa T Burns; 2005 Mar; 31(2):153-8. PubMed ID: 15683685 [TBL] [Abstract][Full Text] [Related]
12. Rational Design of a Chimeric Derivative of PcrV as a Subunit Vaccine Against Wan C; Zhang J; Zhao L; Cheng X; Gao C; Wang Y; Xu W; Zou Q; Gu J Front Immunol; 2019; 10():781. PubMed ID: 31068928 [No Abstract] [Full Text] [Related]
13. Bivalent flagellin immunotherapy protects mice against Pseudomonas aeruginosa infections in both acute pneumonia and burn wound models. Ahmadi H; Behrouz B; Irajian G; Amirmozafari N; Naghavi S Biologicals; 2017 Mar; 46():29-37. PubMed ID: 28065582 [TBL] [Abstract][Full Text] [Related]
14. Epidemiological analysis of serum anti-Pseudomonas aeruginosa PcrV titers in adults. Yasumoto H; Katoh H; Kinoshita M; Shimizu M; Hamaoka S; Akiyama K; Naito Y; Sawa T Microbiol Immunol; 2016 Feb; 60(2):114-20. PubMed ID: 26696420 [TBL] [Abstract][Full Text] [Related]
15. Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia. Hamaoka S; Naito Y; Katoh H; Shimizu M; Kinoshita M; Akiyama K; Kainuma A; Moriyama K; Ishii KJ; Sawa T Microbiol Immunol; 2017 Feb; 61(2):64-74. PubMed ID: 28370521 [TBL] [Abstract][Full Text] [Related]
16. Outer Membrane Vesicles Displaying a Heterologous PcrV-HitA Fusion Antigen Promote Protection against Pulmonary Pseudomonas aeruginosa Infection. Li P; Wang X; Sun X; Guan Z; Sun W mSphere; 2021 Oct; 6(5):e0069921. PubMed ID: 34612675 [TBL] [Abstract][Full Text] [Related]
17. High Throughput Combinatorial Formatting of PcrV Nanobodies for Efficient Potency Improvement. De Tavernier E; Detalle L; Morizzo E; Roobrouck A; De Taeye S; Rieger M; Verhaeghe T; Correia A; Van Hegelsom R; Figueirido R; Noens J; Steffensen S; Stöhr T; Van de Velde W; Depla E; Dombrecht B J Biol Chem; 2016 Jul; 291(29):15243-55. PubMed ID: 27226529 [TBL] [Abstract][Full Text] [Related]